Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A small-molecule inhibitor of BamA impervious to efflux and the outer membrane permeability barrier.

Hart EM, Mitchell AM, Konovalova A, Grabowicz M, Sheng J, Han X, Rodriguez-Rivera FP, Schwaid AG, Malinverni JC, Balibar CJ, Bodea S, Si Q, Wang H, Homsher MF, Painter RE, Ogawa AK, Sutterlin H, Roemer T, Black TA, Rothman DM, Walker SS, Silhavy TJ.

Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21748-21757. doi: 10.1073/pnas.1912345116. Epub 2019 Oct 7.

PMID:
31591200
2.

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.

Young K, Painter RE, Raghoobar SL, Hairston NN, Racine F, Wisniewski D, Balibar CJ, Villafania A, Zhang R, Sahm DF, Blizzard T, Murgolo N, Hammond ML, Motyl MR.

BMC Microbiol. 2019 Jul 4;19(1):150. doi: 10.1186/s12866-019-1522-7.

3.

Inhibitor of intramembrane protease RseP blocks the σE response causing lethal accumulation of unfolded outer membrane proteins.

Konovalova A, Grabowicz M, Balibar CJ, Malinverni JC, Painter RE, Riley D, Mann PA, Wang H, Garlisi CG, Sherborne B, Rigel NW, Ricci DP, Black TA, Roemer T, Silhavy TJ, Walker SS.

Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6614-E6621. doi: 10.1073/pnas.1806107115. Epub 2018 Jun 25.

4.

Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy.

Myers RW, Guan HP, Ehrhart J, Petrov A, Prahalada S, Tozzo E, Yang X, Kurtz MM, Trujillo M, Gonzalez Trotter D, Feng D, Xu S, Eiermann G, Holahan MA, Rubins D, Conarello S, Niu X, Souza SC, Miller C, Liu J, Lu K, Feng W, Li Y, Painter RE, Milligan JA, He H, Liu F, Ogawa A, Wisniewski D, Rohm RJ, Wang L, Bunzel M, Qian Y, Zhu W, Wang H, Bennet B, LaFranco Scheuch L, Fernandez GE, Li C, Klimas M, Zhou G, van Heek M, Biftu T, Weber A, Kelley DE, Thornberry N, Erion MD, Kemp DM, Sebhat IK.

Science. 2017 Aug 4;357(6350):507-511. doi: 10.1126/science.aah5582. Epub 2017 Jul 13.

PMID:
28705990
5.

Antibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase.

Walker SS, Labroli M, Painter RE, Wiltsie J, Sherborne B, Murgolo N, Sher X, Mann P, Zuck P, Garlisi CG, Su J, Kargman S, Xiao L, Scapin G, Salowe S, Devito K, Sheth P, Buist N, Tan CM, Black TA, Roemer T.

PLoS One. 2017 Jul 10;12(7):e0180965. doi: 10.1371/journal.pone.0180965. eCollection 2017.

6.

Affinity Selection-Mass Spectrometry Identifies a Novel Antibacterial RNA Polymerase Inhibitor.

Walker SS, Degen D, Nickbarg E, Carr D, Soriano A, Mandal M, Painter RE, Sheth P, Xiao L, Sher X, Murgolo N, Su J, Olsen DB, Ebright RH, Young K.

ACS Chem Biol. 2017 May 19;12(5):1346-1352. doi: 10.1021/acschembio.6b01133. Epub 2017 Mar 31.

7.

High-throughput screening of antibiotic-resistant bacteria in picodroplets.

Liu X, Painter RE, Enesa K, Holmes D, Whyte G, Garlisi CG, Monsma FJ, Rehak M, Craig FF, Smith CA.

Lab Chip. 2016 Apr 26;16(9):1636-43. doi: 10.1039/c6lc00180g.

PMID:
27033300
8.

Elucidation of DnaE as the Antibacterial Target of the Natural Product, Nargenicin.

Painter RE, Adam GC, Arocho M, DiNunzio E, Donald RG, Dorso K, Genilloud O, Gill C, Goetz M, Hairston NN, Murgolo N, Nare B, Olsen DB, Powles M, Racine F, Su J, Vicente F, Wisniewski D, Xiao L, Hammond M, Young K.

Chem Biol. 2015 Oct 22;22(10):1362-73. doi: 10.1016/j.chembiol.2015.08.015. Epub 2015 Oct 8.

9.

Selective small-molecule inhibition of an RNA structural element.

Howe JA, Wang H, Fischmann TO, Balibar CJ, Xiao L, Galgoci AM, Malinverni JC, Mayhood T, Villafania A, Nahvi A, Murgolo N, Barbieri CM, Mann PA, Carr D, Xia E, Zuck P, Riley D, Painter RE, Walker SS, Sherborne B, de Jesus R, Pan W, Plotkin MA, Wu J, Rindgen D, Cummings J, Garlisi CG, Zhang R, Sheth PR, Gill CJ, Tang H, Roemer T.

Nature. 2015 Oct 29;526(7575):672-7. doi: 10.1038/nature15542. Epub 2015 Sep 30.

PMID:
26416753
10.

Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®.

Blizzard TA, Chen H, Kim S, Wu J, Bodner R, Gude C, Imbriglio J, Young K, Park YW, Ogawa A, Raghoobar S, Hairston N, Painter RE, Wisniewski D, Scapin G, Fitzgerald P, Sharma N, Lu J, Ha S, Hermes J, Hammond ML.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5. doi: 10.1016/j.bmcl.2013.12.101. Epub 2014 Jan 3.

PMID:
24433862
11.

Broadening the spectrum of β-lactam antibiotics through inhibition of signal peptidase type I.

Therien AG, Huber JL, Wilson KE, Beaulieu P, Caron A, Claveau D, Deschamps K, Donald RG, Galgoci AM, Gallant M, Gu X, Kevin NJ, Lafleur J, Leavitt PS, Lebeau-Jacob C, Lee SS, Lin MM, Michels AA, Ogawa AM, Painter RE, Parish CA, Park YW, Benton-Perdomo L, Petcu M, Phillips JW, Powles MA, Skorey KI, Tam J, Tan CM, Young K, Wong S, Waddell ST, Miesel L.

Antimicrob Agents Chemother. 2012 Sep;56(9):4662-70. doi: 10.1128/AAC.00726-12. Epub 2012 Jun 18.

12.

Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus.

Phillips JW, Goetz MA, Smith SK, Zink DL, Polishook J, Onishi R, Salowe S, Wiltsie J, Allocco J, Sigmund J, Dorso K, Lee S, Skwish S, de la Cruz M, Martín J, Vicente F, Genilloud O, Lu J, Painter RE, Young K, Overbye K, Donald RG, Singh SB.

Chem Biol. 2011 Aug 26;18(8):955-65. doi: 10.1016/j.chembiol.2011.06.011.

13.

Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 2. N-Alkylated and open chain analogs of MK-8712.

Chen H, Blizzard TA, Kim S, Wu J, Young K, Park YW, Ogawa AM, Raghoobar S, Painter RE, Wisniewski D, Hairston N, Fitzgerald P, Sharma N, Scapin G, Lu J, Hermes J, Hammond ML.

Bioorg Med Chem Lett. 2011 Jul 15;21(14):4267-70. doi: 10.1016/j.bmcl.2011.05.065. Epub 2011 May 27.

PMID:
21676616
14.

4,7-Dichloro benzothien-2-yl sulfonylaminomethyl boronic acid: first boronic acid-derived beta-lactamase inhibitor with class A, C, and D activity.

Tan Q, Ogawa AM, Painter RE, Park YW, Young K, DiNinno FP.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2622-4. doi: 10.1016/j.bmcl.2010.02.065. Epub 2010 Feb 19.

PMID:
20299220
15.

Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem.

Blizzard TA, Chen H, Kim S, Wu J, Young K, Park YW, Ogawa A, Raghoobar S, Painter RE, Hairston N, Lee SH, Misura A, Felcetto T, Fitzgerald P, Sharma N, Lu J, Ha S, Hickey E, Hermes J, Hammond ML.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):918-21. doi: 10.1016/j.bmcl.2009.12.069. Epub 2009 Dec 23.

PMID:
20044254
16.

Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center.

Woodford N, Tierno PM Jr, Young K, Tysall L, Palepou MF, Ward E, Painter RE, Suber DF, Shungu D, Silver LL, Inglima K, Kornblum J, Livermore DM.

Antimicrob Agents Chemother. 2004 Dec;48(12):4793-9.

17.

Design and synthesis of novel antibacterial agents with inhibitory activity against DNA polymerase III.

Ali A, Aster SD, Graham DW, Patel GF, Taylor GE, Tolman RL, Painter RE, Silver LL, Young K, Ellsworth K, Geissler W, Harris GS.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2185-8.

PMID:
11514166

Supplemental Content

Loading ...
Support Center